Cellosaurus logo
expasy logo

Cellosaurus MCF-7.5C (CVCL_DC70)

[Text version]
Cell line name MCF-7.5C
Synonyms MCF7:5C; MCF-7 clone 5C; 5C
Accession CVCL_DC70
Resource Identification Initiative To cite this cell line use: MCF-7.5C (RRID:CVCL_DC70)
Comments Population: Caucasian.
Characteristics: Undergoes rapid and complete apoptosis in the presence of physiologic concentrations of 17-alpha-estradiol.
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
Disease Invasive breast carcinoma of no special type (NCIt: C4194)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0031 (MCF-7)
Children:
CVCL_C5RV (MCF-7:CFR)
Sex of cell Female
Age at sampling 69Y
Category Cancer cell line
Publications

PubMed=1301400; DOI=10.1016/0303-7207(92)90104-E
Jiang S.-Y., Wolf D.M., Yingling J.M., Chang C.-S., Jordan V.C.
An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.
Mol. Cell. Endocrinol. 90:77-86(1992)

PubMed=9242427
Levenson A.S., Jordan V.C.
MCF-7: the first hormone-responsive breast cancer cell line.
Cancer Res. 57:3071-3078(1997)

PubMed=16333030; DOI=10.1093/jnci/dji400
Lewis J.S., Meeke K., Osipo C., Ross E.A., Kidawi N., Li T.-Y., Bell E., Chandel N.S., Jordan V.C.
Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.
J. Natl. Cancer Inst. 97:1746-1759(2005)

PubMed=32453591; DOI=10.1021/acs.jmedchem.0c00456
Li Y.-F., Zhao J., Gutgesell L.M., Shen Z.-N., Ratia K., Dye K., Dubrovskyi O., Zhao H.-P., Huang F., Tonetti D.A., Thatcher G.R.J., Xiong R.
Novel pyrrolopyridone bromodomain and extra-terminal motif (BET) inhibitors effective in endocrine-resistant ER+ breast cancer with acquired resistance to fulvestrant and palbociclib.
J. Med. Chem. 63:7186-7210(2020)

Cross-references
Cell line databases/resources cancercelllines; CVCL_DC70
Encyclopedic resources Wikidata; Q54904329
Entry history
Entry creation13-Jul-2016
Last entry update05-Oct-2023
Version number13